Merck KGaA to spend €35m to replace filling line at Bari facility

By Gareth Macdonald

- Last updated on GMT

Merck KGaA to spend €35m to replace filling line at Bari facility

Related tags Manufacturing

Merck KGaA will install a new aseptic filling line at its facility in Bari, Italy for multiple sclerosis drugs, fertility treatments and growth hormones.

The German drug manufacture announced the plan last night, explaining it will spend €35m ($41m) to replacing an existing filling line at the facility.

A spokeswoman told us “The new line will replace an existing one, leveraging the latest technological developments while providing an increase in capacity.

She explained the plan “is part of continuous investments in our manufacturing network to maintain state-of-the-art industry level and adapt its capacity to patient needs for our medicines.”

The line will be used to fill Merck’s multiple sclerosis Rebif, its fertility disorder treatments Gonal-f and Ovidrel as well as the growth hormone Saizen. It is due to become operational in 2022.

The Bari facility was established in 1992 as a hub for fill finish activities. Drugs made at the site are shipped to 150 countries.

The new investment is the second in the past five years. In 2014 Merck spent €50m to install a fully automated production line under isolator and set up an automated warehouse at the site.

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Follow us

Webinars

Headlines